/
BNTX
$93.05-$1.21 (-1.28%)live
Held by
1
portfolio on TandT
Bookmarked by
0
users
Avg position size
0.1%
of holders' portfolios
13F filers
1
institution
Market cap
$23.1B
253M shares
52-week range
$79.52 – $124.00
30% from low
Exchange
NASDAQ
ADRC
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-130.95
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $127.6M | $108.6M | $482.3M | $18.98B | $17.31B | $3.82B | $2.75B | $2.76B |
| Cost of revenue | $13.7M | $17.4M | $59.3M | $2.91B | $3.00B | $599.8M | $541.3M | $616.5M |
| Gross profit | $113.9M | $91.2M | $423.0M | $16.07B | $14.32B | $3.22B | $2.21B | $2.14B |
| Gross margin | 89.3% | 84.0% | 87.7% | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| R&D | $143.1M | $226.5M | $645.0M | $949.2M | $1.54B | $1.78B | $2.25B | $2.02B |
| Operating income | −$53.9M | −$181.5M | −$82.4M | $15.28B | $12.64B | $690.4M | −$1.31B | −$623.9M |
| EBITDA | −$24.0M | −$143.8M | −$105.1M | $15.00B | $13.10B | $1.38B | −$367.1M | −$628.0M |
| Net income | −$48.0M | −$179.1M | $15.2M | $10.29B | $9.43B | $930.3M | −$665.3M | −$1.09B |
| Net margin | -37.6% | -164.9% | 3.2% | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| EPS (diluted) | -0.21 | -0.85 | 0.06 | 41.21 | 37.09 | 3.83 | -2.77 | -4.51 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.2B | $-4.65 | $-4.73–$-4.55 | 9 |
| 2027 | $2.2B | $-4.84 | $-6.67–$-2.99 | 9 |
| 2028 | $2.6B | $-4.33 | $-9.45–$-0.70 | 13 |
| 2029 | $2.2B | $-4.74 | $-5.88–$-3.83 | 11 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$47.89
Price
$93.05
Implied downside
-49%
Peer comparison
BioNTech SE American Depositary Share
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
www.biontech.de- Employees
- 7,807
- IPO / List date
- Oct 10, 2019
Held by traders on TradeandTell
| Trader / Portfolio | Conviction |
|---|---|
| Robinhood — Robinhood Individualb | — |
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2025-12-31 | 4,927 | $469.1K |
Insider activity (SEC Form 4)
